John Kovach, president and CEO of Lixte, said: “Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children in mouse models. We have now found that some variants of these compounds have effects on brain cells that are believed to be potentially useful for the treatment of common neurodegenerative brain diseases.
“Since Lixte is focused primarily on developing anticancer drugs, we are exploring partnerships with companies that have expertise and research programs in the treatment of Alzheimer’s disease.”